

## **Supplemental material**

**Number of Supplemental Table:** **6 Tables**

**Number of Supplemental Figure:** **3 Figures**

**Table S1A. Assays and Manufactures for C-Reactive Protein Measurements**

Assays	Manufactures
Latex agglutination	EIKEN CHEMICAL CO.,LTD. SEKISUI MEDICAL CO., LTD. NITTOBO MEDICAL CO.,LTD. FUJIFILM Wako Pure Chemical Corporation LSI Medience Corporation.
Latex turbidimetry	Shino-Test Corporation. LSI Medience Corporation. Roche Diagnostics K.K.

**Table S1B. Assays and Manufactures D-dimer Measurements**

Assays	Manufactures
Latex agglutination	LSI Medience Corporation. bioMérieux Japan Ltd. Roche Diagnostics K.K.
Latex turbidimetry	LSI Medience Corporation. bioMérieux Japan Ltd. Roche Diagnostics K.K. Sysmex Corporation. SEKISUI MEDICAL CO., LTD. KAINOS Laboratories, Inc. KYOKUTO PHARMACEUTICAL INDUSTRIAL CO., LTD.

**Table S2. Univariate cox proportional hazard analysis for predictor of in-hospital mortality**

Variables	HR	CI	p
Demographics and medical history			
Age	1.05	1.03	1.07
Male	1.48	0.88	2.47
Japanese	21.10	0.06	7995.92
BMI	1.00	0.94	1.05
Comorbidities			
Hypertension	1.16	0.70	1.92
Diabetes mellitus	0.81	0.51	1.30
Dyslipidemia	0.73	0.45	1.18
Heart failure	1.59	0.85	2.94
Coronary artery disease	2.41	1.36	4.24
Myocardial infarction	1.58	0.72	3.46
CI/TIA	0.96	0.47	1.95
Chronic lung disease	3.11	1.63	5.91
CKD	1.73	0.93	3.21
Cancer	2.53	1.41	4.56
Symptoms			
Fever (> 38.0°C)	1.67	0.95	2.92
Cough	1.10	0.70	1.74
Pharyngitis	0.48	0.17	1.34
Rhinorrhea	0.86	0.26	2.84
Dyspnea	1.50	0.95	2.36
Arthritis	1.16	0.37	3.70
Headache	0.05	0.00	2.82
Olfactory dysfunction	0.05	0.00	4.02
Asymptom	0.56	0.18	1.79
Physical findings			
Max body temperature	1.38	1.04	1.84
Herat rate	1.02	1.00	1.03
Systolic BP	0.99	0.99	1.00
Respiratory rate	1.06	1.02	1.11
SpO2	0.95	0.92	0.98
Laboratory data at admission			
White blood cell	1.00	1.00	1.00
Lymphocyte	0.96	0.94	0.99

Neutrocyte	1.03	1.01	1.05	0.019
Eosinocyte	0.70	0.50	0.98	0.038
Hemoglobin	0.92	0.83	1.02	0.096
Platelet	0.95	0.91	0.98	0.001
Creatinin	1.14	1.04	1.24	0.003
eGFR	0.99	0.98	1.00	0.002
LDH	1.00	1.00	1.00	<0.001
HbA1c	0.80	0.60	1.07	0.137
CK	1.00	1.00	1.00	0.689
Serum Alb	0.51	0.36	0.73	<0.001
Specific biomarker at admission				
CRP	1.03	1.00	1.05	0.029
D-dimer	1.00	1.00	1.01	0.341
FDP	1.00	1.00	1.00	0.989
Ferritin	1.00	1.00	1.00	0.602
Procalcitonin	1.00	0.98	1.03	0.725
IL-6	1.00	0.99	1.01	0.944
KL-6	1.00	1.00	1.00	0.001
Both CRP and D-dimer were above Middle	3.46	1.72	6.96	<0.001

Data are shown as mean ± standard deviation or median with interquartile range or percentage. Variables of laboratory data were analyzed as continuous variables, except for cumulative variable of CRP and D-dimer. BMI: body mass index, CI: cerebral infarction, TIA: transient ischemic attack, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, BP: blood pressure, eGFR: estimated glomerular filtration rate, LDH: lactic acid dehydrogenase, HbA1c: hemoglobin A1c, CK: creatine kinase, Alb: albumin, CRP: C-reactive protein, FDP: fibrin degradation products, KL-6: Krebs von den Lungen-6 antigen.

**Table S3. Multivariate cox proportional hazard analysis for predictor of in-hospital mortality**

Variables	HR	CI	p
Demographics and medical history			
Age	1.07	1.023	1.111
Coronary artery disease	3.39	1.358	8.445
COPD	1.18	0.353	3.917
CKD	1.92	0.592	6.195
Cancer	0.66	0.213	2.042
Dyspnea	0.85	0.360	1.989
Max body temperature	1.56	0.980	2.472
Herat rate	1.02	0.993	1.039
SpO2	0.96	0.899	1.034
White blood cell	1.00	1.000	1.000
Hemoglobin	1.04	0.829	1.299
Platelet	0.92	0.857	0.992
LDH	1.00	0.998	1.004
Serum Alb	0.83	0.315	2.189
KL-6	1.00	1.000	1.002
Both CRP and D-dimer were above Middle	3.88	1.185	12.728
			0.025

The Cox proportional hazard model predicting the odds of in-hospital mortality, adjusted for demographics and clinical comorbidities. Variables of laboratory data were analyzed as continuous variables, except for cumulative variable of CRP and D-dimer. Covariates included in the multivariable were selected based on univariate analyses.

HR: hazard ratio, CI: confidence interval, BMI: body mass index, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, LDH: lactic acid dehydrogenase, Alb: albumin, KL-6: Krebs von den Lungen-6 antigen, CRP: C-reactive protein.

**Table S4. Biomarker levels at each timing of admission, peak, and final examination**

	In-hospital death (n=108)	n	Non in-hospital death (n=585)	n	P Value
CRP, mg/L					
At admission	107.2 (56.9 – 168.9)	108	49.6 (13.4 – 104.5)	559	<0.001
Peak	247.6 (153.3 – 326.7)	104	816.2 (301.5 – 1524.3)	544	<0.001
Final	156.0 (748.5 – 2374.5)	92	4.7 (1.4 – 17.5)	484	<0.001
D-dimer, mg/L					
At admission	2.15 (1.32 - 5.08)	76	1.30 (0.70 - 2.60)	385	<0.001
Peak	14.1 (3.7 - 51.9)	82	2.40 (1.00 - 7.12)	403	<0.001
Final	14.2 (5.93 - 36.1)	58	1.90 (1.01 - 4.00)	239	<0.001

CRP: C-reactive protein.

**Table S5. The increment of biomarker values between baseline and peak**

	In-hospital death (n=108)	n	Non in-hospital death (n=585)	n	P Value
CRP, mg/L	117.1 (15.1 – 209.2)	104	0.15 (0.00 – 52.3)	544	<0.001
D-dimer, mg/L	6.05 (0.00 - 31.1)	74	0.00 (0.00 - 2.69)	376	<0.001
FDP, µg/mL	1.3 (0.00 - 50.0)	50	0.00 (0.00 - 2.90)	158	0.004
Ferritin, ng/mL	29.5 (0.00 - 750.0)	40	0.00 (0.00 - 15.0)	271	0.001
Procalcitonin, ng/mL	0.22 (0.00 - 2.14)	52	0.00 (0.00 - 0.00)	205	<0.001
KL6, U/mL	0.00 (0.00 - 269.0)	46	0.00 (0.00 - 0.00)	240	0.002

CRP: C-reactive protein, FDP: fibrin degradation products, KL-6: Krebs von den Lungen-6 antigen.

**Table S6. Timing of peak value of each biomarker (Days from discharge)**


	In-hospital death (n=108)	n	Non in-hospital death (n=585)	n	P Value
CRP	4.5 (0.25 - 14.0)	104	15.0 (9.0 - 24.0)	546	<0.001
D-dimer	5.0 (1.0 - 13.0)	82	13.5 (8.0 - 23.8)	404	<0.001
FDP	8.0 (1.0 - 22.0 )	59	16.0 (9.0 - 28.0)	179	0.001
Ferritin	7.0 (1.0 - 19.0)	49	15.0 (9.8 - 25.3)	302	<0.001
Procalcitonin	8.0 (2.0 - 23.0 )	55	17.0 (11.0 - 24.0)	222	0.001
KL6	8.5 (5.3 - 18.8)	48	14.0 (8.0 - 25.0)	267	0.012

CRP: C-reactive protein, FDP: fibrin degradation products, KL-6: Krebs von den Lungen-6 antigen.


## Supplemental Figure

**Figure S1**


**(A)**



**(B)**




**Figure S2**






**Figure S3****(A)**

CRP


**(B)**

D-dimer



**(C)****(D)**

(E)



## **Supplemental Figure Legend**

Figure S1: Sensitivity analysis with additional threshold values to evaluate the incidence of in-hospital death. Threshold values were: (A) CRP, 92.0 mg/L; D-dimer, 2.28 mg/L, and (B) CRP, 50.0 mg/L; D-dimer, 1.00 mg/L. CRP: C-reactive protein. CRP: C-reactive protein.

Figure S2: Proportion of patients whose peak CRP and D-dimer values were recorded at the indicated time points (days from admission). CRP: C-reactive protein.

Figure S3: Trajectories of other biomarkers over time among survival and in-hospital deaths. (A) CRP, (B) D-dimer, (C) ferritin, (D) procalcitonin, and (E) KL-6. CRP: C-reactive protein.